11.06.15
Vital Art and Science LLC (VAS) has received a U.S. patent for its mVT Service, a U.S. Food and Drug Administration (FDA)-cleared prescription medical device that accurately tracks changes caused by age-related macular degeneration (AMD) and diabetic retinopathy (DR). Use of the device enables clinicians to catch disease progression early when it is most responsive to treatment.
Patent No. 9,033,508 addresses a breakthrough approach for handheld visual function testing with a touchscreen display that communicates results including time and date to a database, the company claims.
“We are pleased to add this new patent to our expanding IP portfolio,” said Mike Bartlett, company president. “The ability to catch disease changes early generally results in earlier treatment and better visual outcomes. And that’s what makes this patent, and the mVT Service important.”
Bartlett said the company’s expanded patent portfolio and clinical test results have created significant interest from pharmaceutical companies. “They appreciate the value of the mVT, especially in clinical studies for longer duration compounds under development,” he noted.
In April 2015, VAS announced the launch of the mVT. Company executives claim the mVT Service is the only FDA-cleared, low-cost, mobile, validated method available for patients to test their vision at home. Patients take a four- to six-minute self-test, performed on the timetable recommended by the doctor (usually twice a week). Patient test results automatically are delivered to a HIPAA-compliant database and analyzed. A significant change sends an automatic alert to the prescriber, who charts a needed course of action. AMD is the leading cause of blindness for people over 60, and DR vision loss continues to grow with the increasing prevalence of diabetes.
Vital Art and Science has developed a patented, clinically validated ophthalmic medical device available on the Apple App Store for patients diagnosed or concerned about maculopathy. The firm is based in Richardson, Texas.
Patent No. 9,033,508 addresses a breakthrough approach for handheld visual function testing with a touchscreen display that communicates results including time and date to a database, the company claims.
“We are pleased to add this new patent to our expanding IP portfolio,” said Mike Bartlett, company president. “The ability to catch disease changes early generally results in earlier treatment and better visual outcomes. And that’s what makes this patent, and the mVT Service important.”
Bartlett said the company’s expanded patent portfolio and clinical test results have created significant interest from pharmaceutical companies. “They appreciate the value of the mVT, especially in clinical studies for longer duration compounds under development,” he noted.
In April 2015, VAS announced the launch of the mVT. Company executives claim the mVT Service is the only FDA-cleared, low-cost, mobile, validated method available for patients to test their vision at home. Patients take a four- to six-minute self-test, performed on the timetable recommended by the doctor (usually twice a week). Patient test results automatically are delivered to a HIPAA-compliant database and analyzed. A significant change sends an automatic alert to the prescriber, who charts a needed course of action. AMD is the leading cause of blindness for people over 60, and DR vision loss continues to grow with the increasing prevalence of diabetes.
Vital Art and Science has developed a patented, clinically validated ophthalmic medical device available on the Apple App Store for patients diagnosed or concerned about maculopathy. The firm is based in Richardson, Texas.
a patented, clinically validated, and FDA cleared Ophthalmic medical device that is available on the Apple App Store for all patients diagnosed with or concerned about maculopathy. - See more at: http://www.myvisiontrack.com/about#sthash.uaGBJxvG.dpuf